InMed Pharmaceuticals, Inc. (NASDAQ: INM) (“InMed” or the “Company”) is pleased to announce that it has entered into a definitive merger agreement (the “Agreement”) for an all-stock transaction with Mentari Therapeutics, Inc. (“Mentari”), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. The merger brings together Mentari’s differentiated migraine pipeline with InMed’s public market infrastructure, positioning the combined company to expedite the development of new therapies for people living with migraine.
Read the full article: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies //
Source: https://www.prnewswire.com/news-releases/inmed-pharmaceuticals–mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies-302776112.html